论文部分内容阅读
[目的]探讨川芎嗪(TMP)对人乳腺癌MCF-7/ADM细胞的耐药逆转及其对该细胞P-糖蛋白(P-gp)表达的影响.[方法]MTT法测定细胞的药敏性和抗药性逆转,流式细胞术检测耐药细胞P-糖蛋白的表达.[结果]非细胞毒性剂量(320μg/m l)和低毒剂量(1 250μg/m l)的川芎嗪均能显著降低MCF-7/ADM细胞的IC50(P<0.01),逆转倍数分别为2.14和2.80倍;并使该细胞P-gp的表达率由(90.60±0.40)%分别降低至(69.10±1.65)%和(60.30±1.25)%.[结论]川芎嗪可部分逆转人乳腺癌MCF-7/ADM细胞对阿霉素的耐药性,其逆转机制与抑制该细胞P-gp的表达有关.
[Objective] To investigate the reversal of multidrug resistance in human breast cancer cell line MCF-7 / ADM by ligustrazine (TMP) and its effect on the expression of P-glycoprotein (P-gp). [Methods] (P <0.05). [Results] Ligustrazine in non-cytotoxic dose (320μg / ml) and low dose (1 250μg / ml) The IC50 of MCF-7 / ADM cells decreased (2.14 and 2.80 fold, respectively), and the expression of P-gp in the cells decreased from (90.60 ± 0.40)% to (69.10 ± 1.65)% And (60.30 ± 1.25)% respectively. [Conclusion] Tetramethylpyrazine can partially reverse the drug resistance to doxorubicin in human breast cancer MCF-7 / ADM cells, and its reversal mechanism is related to the inhibition of P-gp expression.